Brief: BriaCell Secures License For A Promising Novel Anti-Cancer Agent
04/08/2022 14:42
Aug 4 (Reuters) - BriaCell Therapeutics Corp BCT.TO :
* BRIACELL SECURES LICENSE FOR A PROMISING NOVEL ANTI-CANCER
AGENT
* BRIACELL THERAPEUTICS CORP - UNDER TERMS OF AGREEMENT,
BRIACELL
GAINS WORLDWIDE RIGHTS TO DEVELOP AND COMMERCIALIZE SCD80
* BRIACELL THERAPEUTICS CORP - BRIACELL WILL PAY ROYALTIES
TO UMBC
UPON COMMERCIALIZATION OF PRODUCT PLUS PATENT MANAGEMENT COSTS
Source text for Eikon: ID:nGNX4yCPG5
Further company coverage: BCT.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Briacell Therapeutics
See all newsBrief: Briacell Therapeutics Prices 1.45 Million Common Shares At $3.25 Per Share
Brief: Briacell Receives Positive Recommendation From Data Safety Monitoring Board (Dsmb) For Phase 3 Study In Metastatic Breast Cancer
Brief: Briacell Expands Pipeline To Include An Ovarian Cancer Immunotherapy Candidate, Bria-Ova+™
Brief: Briacell Phase 3 Bria-Imt™ Study Enrollment Surpasses 230 Patients
Brief: Briacell Adds Nyu Langone Health’S Perlmutter Cancer Center As Clinical Site In Pivotal Phase 3 Breast Cancer Study